Susan Raber
Impact in
-
- Antibiotic Use and Resistance
- Molecular Medicine top 5%
- Antibiotic Resistance in Bacteria
Papers in
-
- Antibiotic Use and Resistance 3
-
- Antibiotic Resistance in Bacteria 6
- Co-authors
- Keith A. RodvoldDavid N. GilbertJ. E. LeggettR J DworkinSusan K. ChuckKurt FuurstedJenny Dahl KnudsenNiels Frimodt‐Møller
- Journals
- Clinical Pharmacology & Therapeutics (6 papers)Investigative Ophthalmology & Visual Science (3 papers)The Pediatric Infectious Disease Journal (3 papers)Cancer (2 papers)Antimicrobial Agents and Chemotherapy (2 papers)
- Partner nations
- United StatesUnited KingdomGermany
In The Last Decade
Susan Raber
33 papers receiving 616 citations
Peers
Comparison fields: 5 of 87
- Applied Microbiology and Biotechnology 47
- Molecular Medicine 99
- Pharmacology 283
- Clinical Biochemistry 51
- Ophthalmology 65
Countries citing papers authored by Susan Raber
This map shows the geographic impact of Susan Raber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan Raber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan Raber more than expected).
Fields of papers citing papers by Susan Raber
This network shows the impact of papers produced by Susan Raber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan Raber. The network helps show where Susan Raber may publish in the future.
Co-authors
The 25 scholars most cited alongside Susan Raber, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 2 | |
| 3 | 2024 | 11 | |
| 4 | 2020 | 16 | |
| 5 | 2019 | 16 | |
| 6 | 2015 | 4 | |
| 7 | 2015 | 44 | |
| 8 | 2011 | 42 | |
| 9 | 2011 | 18 | |
| 10 | Dose-Escalating, Double-Masked, Vehicle-Controlled Trial of the IOP-Reducing Effect of the EP2 Agonist PF-04217329 | 2010 | 2 |
| 11 | 2010 | 12 | |
| 12 | Efficacy and Safety of PF-03187207, A Novel Nitric Oxide Donating Prostaglandin F2-Alpha Analogue, vs. Latanoprost in Hypertensive Eyes | 2009 | 3 |
| 13 | A Model-Based Dose-Response Meta-Analysis of Single Agent Intraocular Pressure (IOP) Therapies Used to Evaluate Efficacy of a Potential New Therapy (PF-03187207) in Glaucoma Patients | 2009 | 1 |
| 14 | 2007 | 29 | |
| 15 | 2007 | 2 | |
| 16 | 2006 | 4 | |
| 17 | 2004 | 14 | |
| 18 | 2000 | 75 | |
| 19 | 1997 | 88 | |
| 20 | 1994 | 62 |
About Susan Raber
Susan Raber is a scholar working on Applied Microbiology and Biotechnology, Molecular Medicine, Ophthalmology, Pharmacology and Epidemiology, having authored 33 papers that have together received 628 indexed citations. Recurring topics across this work include Antibiotics Pharmacokinetics and Efficacy (12 papers), Pneumonia and Respiratory Infections (7 papers), Glaucoma and retinal disorders (7 papers), Antibiotic Resistance in Bacteria (6 papers), Retinal Diseases and Treatments (4 papers), Ocular Surface and Contact Lens (4 papers), Antibiotic Use and Resistance (3 papers) and Corneal surgery and disorders (3 papers). The work is most often cited by research in Applied Microbiology and Biotechnology (47 citations), Molecular Medicine (99 citations), Pharmacology (283 citations), Clinical Biochemistry (51 citations) and Ophthalmology (65 citations). Susan Raber has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Keith A. Rodvold, David N. Gilbert, J. E. Leggett, R J Dworkin, Susan K. Chuck, Kurt Fuursted, Jenny Dahl Knudsen, Niels Frimodt‐Møller, Rachel Courtney and F. Espersen. Their work appears in journals such as Clinical Pharmacology & Therapeutics, Investigative Ophthalmology & Visual Science, The Pediatric Infectious Disease Journal, Cancer and Antimicrobial Agents and Chemotherapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.